Next Article in Journal
Anticoagulation in the Elderly
Next Article in Special Issue
Pharmacogenetics of SSRIs and Sexual Dysfunction
Previous Article in Journal
Obesity Drug Update: The Lost Decade?
Previous Article in Special Issue
Beneficial Effects of Tianeptine on Hippocampus-Dependent Long-Term Memory and Stress-Induced Alterations of Brain Structure and Function
Pharmaceuticals 2010, 3(12), 3522-3542; doi:10.3390/ph3123522
Review

Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder

,
 and *
Institute of Mental Health, Department of Psychiatry, University of British Columbia, 5950 University Blvd. Vancouver, BC V6T 1Z3, Canada
* Author to whom correspondence should be addressed.
Received: 1 November 2010 / Revised: 24 November 2010 / Accepted: 2 December 2010 / Published: 3 December 2010
(This article belongs to the Special Issue Antidepressants)
View Full-Text   |   Download PDF [161 KB, 8 December 2010; original version 3 December 2010]

Abstract

Antidepressant therapies, such as selective serotonin reuptake inhibitors (SSRIs), are current first-line treatments for Major Depressive Disorder. However, over 50% of treated patients show an inadequate response to initial antidepressant therapy. If the therapeutic outcomes from two antidepressant therapies are suboptimal, potentially resulting in Treatment Resistant Depression, subsequent strategies include switching to another antidepressant or augmenting treatment by combining with other agents. When combined with SSRIs, atypical antipsychotics have supplementary action on dopaminergic and noradrenergic systems. Studies on combined treatment with atypical antipsychotics have shown significantly increased remission rates, shortened response times, and favorable side effects. Augmentation of antidepressants with atypical antipsychotics is now an acceptable treatment strategy which leads to increased remission rates and better outcomes for patients.
Keywords: treatment resistant disorder; major depressive disorder; augmentation; atypical antipsychotic; typical antipsychotic; antidepressant; selective serotonin reuptake inhibitor; electroconvulsive therapy treatment resistant disorder; major depressive disorder; augmentation; atypical antipsychotic; typical antipsychotic; antidepressant; selective serotonin reuptake inhibitor; electroconvulsive therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Seo, R.J.; MacPherson, H.; Young, A.H. Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder. Pharmaceuticals 2010, 3, 3522-3542.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert